Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review

Detalhes bibliográficos
Autor(a) principal: Barros, Igor Almeida de Moura
Data de Publicação: 2022
Outros Autores: Ferraz, Gabriela De Morais Guerra, Cavalcanti , Ully Dias Nascimento Tavora
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/32195
Resumo: Background: COVID-19 is an inflammatory disease caused by SARS-CoV-2, in which the patient can progress to a hypercoagulable state, requiring antithrombotic therapy. Objectives: To describe data from the literature on the use of anticoagulants as a treatment for COVID-19 positive patients and their impact on the oral cavity, the platelet antiaggregants and anticoagulants used to aid in the treatment of the Covid-positive patient, the exams and markers that help the choice of the therapy to be used, as well as observing the treatment and associating it with the risk of oral bleeding. Methodology: A bibliographic survey was carried out from 2012 to 2021 in the BvSalud research base. The keywords “Covid”, “anticoagulants” and “risk factors” and their corresponding words in English “Covid”, “anticoagulants and “risk factors” were used. Results: 128 articles were selected in BvSalud, after reading 68 articles were excluded, leaving 60 articles that met the criteria for literature review. Conclusion: Covid-19 is a pathology that acts on ACE2 receptors, triggering an inflammatory response and activating the coagulation cascade, hematological tests (D-dimer, fibrinogen, ferritin, prothrombin time, interleukin-6 and Protein-C- reactive) can be used to assess the patient's status. The decision to initiate anticoagulant or antiplatelet therapy should be made after evaluating these markers. Such therapy can exacerbate bleeding resulting from oral trauma at the time of intubation or from preexisting ulcers or ulcers acquired after ICU admission, the installation of ETT requires special care with the patient's oral hygiene, in view of the greater susceptibility to secondary infections.
id UNIFEI_8d55a2c968b342dd737812e60c5f4acc
oai_identifier_str oai:ojs.pkp.sfu.ca:article/32195
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a reviewTerapia anticoagulante para el tratamiento del COVID-19 y su impacto en la cavidad oral: una revisiónO uso de anticoagulantes para o tratamento da COVID-19 e sua repercussão na cavidade oral: revisão de literaturaCovid-19AnticoagulantsRisk factors.Covid-19AnticoagulantesFactores de riesgo.Covid-19AnticoagulantesFatores de risco.Background: COVID-19 is an inflammatory disease caused by SARS-CoV-2, in which the patient can progress to a hypercoagulable state, requiring antithrombotic therapy. Objectives: To describe data from the literature on the use of anticoagulants as a treatment for COVID-19 positive patients and their impact on the oral cavity, the platelet antiaggregants and anticoagulants used to aid in the treatment of the Covid-positive patient, the exams and markers that help the choice of the therapy to be used, as well as observing the treatment and associating it with the risk of oral bleeding. Methodology: A bibliographic survey was carried out from 2012 to 2021 in the BvSalud research base. The keywords “Covid”, “anticoagulants” and “risk factors” and their corresponding words in English “Covid”, “anticoagulants and “risk factors” were used. Results: 128 articles were selected in BvSalud, after reading 68 articles were excluded, leaving 60 articles that met the criteria for literature review. Conclusion: Covid-19 is a pathology that acts on ACE2 receptors, triggering an inflammatory response and activating the coagulation cascade, hematological tests (D-dimer, fibrinogen, ferritin, prothrombin time, interleukin-6 and Protein-C- reactive) can be used to assess the patient's status. The decision to initiate anticoagulant or antiplatelet therapy should be made after evaluating these markers. Such therapy can exacerbate bleeding resulting from oral trauma at the time of intubation or from preexisting ulcers or ulcers acquired after ICU admission, the installation of ETT requires special care with the patient's oral hygiene, in view of the greater susceptibility to secondary infections.Fundamentos: A COVID-19 é uma doença inflamatória causó pelo SARS-CoV-2, na qual p paciente pode evoluir para um estado hipercoagulavel, necesitándose de terapia antitrombótica. Objetivos: Descrever dados da literatura sobre o uso de anticoagulantes como tratamiento para pacientes COVID-19 positivo y su repercussão na cavidade oral, os antiagregantes plaquetários e anticoagulantes utilizados para auxilio de tratamiento de pacientes COVID -positivo, os exames e marcadores que auxiliam a escolha da terapia a ser utilizada, así como observar o tratar y asociar ao riesgo de hemorragia oral. Metodología: Foi realizado um levantamiento bibliográfico no período de 2012 a 2021 na base de pesquisa BvSalud. Foram usó as palavras-chaves “ COVID ”, “anticoagulantes” e “fatores de risco” y seus correspondientes em inglês “ COVID ”, “anticoagulants e “riskfactors”. Results: Foram selecionados 128 artigos na BvSalud, após a leitura foram excluídos 68 artigos, restando 60 artigos that adentiam os critérios for revisão de literatura. Conclusión: A COVID -19 é uma patologia que age sobre os receptores ECA2, desencadeando uma resposta inflamatória e ativando a cascata de coagulação, exames hematológicos (D-dimero, fibrinogenio, ferritina, tempo de protrombina, interleucina-6 and Proteina-C- reativa) puede ser utilizado para evaluar o estado del paciente. Una decisión de iniciar una terapia anticoagulante o antiagregante deve ocorrer después de una evaluación de los marcadores. Tal terapia puede exacerbar sangramentos decorativos de traumas o no hay momento de intubação ou de úlceras preexistentes ou adquiridas después de admisión en UTI, una instalación do TET requiere cuidados especiales com a higiene oral del paciente, tendo em vista a maior susceptibilidade as infecções secundárias.Fundamentos: A COVID-19 é uma doença inflamatória causada pelo SARS-CoV-2, na qual p paciente pode evoluir para um estado hipercoagulavel, necessitando de terapia antitrombótica. Objetivos: Descrever dados da literatura sobre o uso de anticoagulantes como tratamento para pacientes COVID-19 positivo e sua repercussão na cavidade oral, os antiagregantes plaquetários e anticoagulantes utilizados para auxílio de tratamento do paciente Covid-positivo, os exames e marcadores que auxiliam a escolha da terapia a ser utilizada, assim como observar o tratamento e associar ao risco de hemorragia oral. Metodologia: Foi realizado um levantamento bibliográfico no período de 2012 a 2021 na base de pesquisa BvSalud. Foram utilizadas as palavras-chaves “Covid”, “anticoagulantes” e “fatores de risco” e seus correspondentes em inglês “Covid”, “anticoagulants e “risk factors”. Resultados: Foram selecionados 128 artigos na BvSalud, após a leitura foram excluídos 68 artigos, restando 60 artigos que atendem os critérios para revisão de literatura. Conclusão: A Covid-19 é uma patologia que age sobre os receptores ECA2, desencadeando uma resposta inflamatória e ativando a cascata de coagulação, exames hematológicos (D-dimero, fibrinogenio, ferritina, tempo de protrombina, interleucina-6 e Proteina-C-reativa) podem ser utilizados para avaliar o estado do paciente. A decisão de iniciar a terapia anticoagulante ou antiagregante deve ocorrer após a avaliação desses marcadores. Tal terapia pode exacerbar sangramentos decorrentes de traumas orais no momento de intubação ou de úlceras preexistentes ou adquiridas após admissão em UTI, a instalação do TET requer cuidados especiais com a higiene oral do paciente, tendo em vista a maior susceptibilidade as infecções secundárias.Research, Society and Development2022-07-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3219510.33448/rsd-v11i9.32195Research, Society and Development; Vol. 11 No. 9; e59611932195Research, Society and Development; Vol. 11 Núm. 9; e59611932195Research, Society and Development; v. 11 n. 9; e596119321952525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/32195/27485Copyright (c) 2022 Igor Almeida de Moura Barros; Gabriela De Morais Guerra Ferraz; Ully Dias Nascimento Tavora Cavalcanti https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBarros, Igor Almeida de Moura Ferraz, Gabriela De Morais Guerra Cavalcanti , Ully Dias Nascimento Tavora 2022-07-21T12:36:16Zoai:ojs.pkp.sfu.ca:article/32195Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:48:16.409660Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review
Terapia anticoagulante para el tratamiento del COVID-19 y su impacto en la cavidad oral: una revisión
O uso de anticoagulantes para o tratamento da COVID-19 e sua repercussão na cavidade oral: revisão de literatura
title Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review
spellingShingle Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review
Barros, Igor Almeida de Moura
Covid-19
Anticoagulants
Risk factors.
Covid-19
Anticoagulantes
Factores de riesgo.
Covid-19
Anticoagulantes
Fatores de risco.
title_short Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review
title_full Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review
title_fullStr Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review
title_full_unstemmed Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review
title_sort Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review
author Barros, Igor Almeida de Moura
author_facet Barros, Igor Almeida de Moura
Ferraz, Gabriela De Morais Guerra
Cavalcanti , Ully Dias Nascimento Tavora
author_role author
author2 Ferraz, Gabriela De Morais Guerra
Cavalcanti , Ully Dias Nascimento Tavora
author2_role author
author
dc.contributor.author.fl_str_mv Barros, Igor Almeida de Moura
Ferraz, Gabriela De Morais Guerra
Cavalcanti , Ully Dias Nascimento Tavora
dc.subject.por.fl_str_mv Covid-19
Anticoagulants
Risk factors.
Covid-19
Anticoagulantes
Factores de riesgo.
Covid-19
Anticoagulantes
Fatores de risco.
topic Covid-19
Anticoagulants
Risk factors.
Covid-19
Anticoagulantes
Factores de riesgo.
Covid-19
Anticoagulantes
Fatores de risco.
description Background: COVID-19 is an inflammatory disease caused by SARS-CoV-2, in which the patient can progress to a hypercoagulable state, requiring antithrombotic therapy. Objectives: To describe data from the literature on the use of anticoagulants as a treatment for COVID-19 positive patients and their impact on the oral cavity, the platelet antiaggregants and anticoagulants used to aid in the treatment of the Covid-positive patient, the exams and markers that help the choice of the therapy to be used, as well as observing the treatment and associating it with the risk of oral bleeding. Methodology: A bibliographic survey was carried out from 2012 to 2021 in the BvSalud research base. The keywords “Covid”, “anticoagulants” and “risk factors” and their corresponding words in English “Covid”, “anticoagulants and “risk factors” were used. Results: 128 articles were selected in BvSalud, after reading 68 articles were excluded, leaving 60 articles that met the criteria for literature review. Conclusion: Covid-19 is a pathology that acts on ACE2 receptors, triggering an inflammatory response and activating the coagulation cascade, hematological tests (D-dimer, fibrinogen, ferritin, prothrombin time, interleukin-6 and Protein-C- reactive) can be used to assess the patient's status. The decision to initiate anticoagulant or antiplatelet therapy should be made after evaluating these markers. Such therapy can exacerbate bleeding resulting from oral trauma at the time of intubation or from preexisting ulcers or ulcers acquired after ICU admission, the installation of ETT requires special care with the patient's oral hygiene, in view of the greater susceptibility to secondary infections.
publishDate 2022
dc.date.none.fl_str_mv 2022-07-20
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/32195
10.33448/rsd-v11i9.32195
url https://rsdjournal.org/index.php/rsd/article/view/32195
identifier_str_mv 10.33448/rsd-v11i9.32195
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/32195/27485
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 9; e59611932195
Research, Society and Development; Vol. 11 Núm. 9; e59611932195
Research, Society and Development; v. 11 n. 9; e59611932195
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052769158299648